feedback

Course Director

Sara M. Tinsley, PhD, ARNP, AOCN
Sara M. Tinsley, PhD, ARNP, AOCN

Moffitt Cancer Center
University of South Florida, College of Nursing
​Tampa, Florida​

Faculty

Ilene Galinsky
Ilene Galinsky, BSN, MSN, ANP-C

Dana-Farber Cancer Institute
Boston, Massachusetts

Natasha Johnson
Natasha Johnson, MSN, ARNP, AOCNP

Moffitt Cancer Center
Tampa, Florida

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CE
Credit Amount:1.5 Credits
Release Date:2017-Jun-20
Expiration Date:2018-Jun-19
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Oncology nurse professionals play a critical role in the management of patients with acute myeloid leukemia (AML), a challenging disease where standard treatments have historically shown limited benefit in some patient populations. That appears likely to change, as the therapeutic landscape in AML is poised to expand with the potential validation of newer cytotoxic and targeted options for patient management. New ways to treat patients, along with a modern understanding of AML disease classifications, molecular mutations, and the impact of cytogenetics on prognosis may finally improve upon conventional care in a number of different AML settings.

In this activity, based on a live symposium held at the annual ONS congress in 2017, Sara M. Tinsley, PhD, ARNP, AOCN, leads an engaging discussion on key aspects of modern AML care, the development of newer therapeutics, and the clinical implications for nurse professionals. Throughout, the speakers share cases from the front lines of practice to illustrate exactly how nurses are using the science on novel agent classes in their daily care. The expert panel further explores how nurse professionals can manage safety considerations with newer therapies in a range of AML populations while offering appropriate emotional and logistical support to individuals suffering from this disease.

Upon completion of this activity, participants will be able to:
  • Effectively communicate with patients on the wide diversity of AML presentations, including clinical implications of high-risk disease, mutated molecular features, early versus late relapse, and secondary AML
  • Review evidence on the safety and efficacy of novel and emerging treatments in AML
  • Manage treatment-emergent toxicity with novel therapeutics in patients with newly diagnosed and previously treated AML
  • Counsel patients on the optimal application of novel cytotoxic and targeted treatment options in the different AML settings

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of acute myeloid leukemia.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of AML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 20, 2017 - June 19, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity during the past 12 months.

Course Director and Moderator
Sara M. Tinsley, PhD, ARNP, AOCN
Nurse Practitioner, Malignant Hematology
Moffitt Cancer Center
Assistant Professor
University of South Florida, College of Nursing
Tampa, Florida

Sara M. Tinsley, PhD, ARNP, AOCN, has a financial interest/relationship or affiliation in the form of:
Consultant for Celgene Corporation.
Speakers Bureau participant with ARIAD Pharmaceuticals, Inc.; Celgene Corporation; Incyte Corporation; and Novartis Pharmaceuticals Corporation.
Advisory Board for Celgene Corporation and Genentech, Inc.

Sara M. Tinsley, PhD, ARNP, AOCN, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: including novel cytotoxic therapy, IDH, FLT3, and Bcl-2 inhibitors currently being evaluated in AML.

Faculty
Ilene Galinsky, BSN, MSN, ANP-C
Senior Program Research Nurse Practitioner Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ilene Galinsky, BSN, MSN, ANP-C, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Novartis Pharmaceuticals Corporation and Pfizer, Inc.

Ilene Galinsky, BSN, MSN, ANP-C, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: including IDH, FLT3, and Bcl-2 inhibitors, among other targeted agents, currently being evaluated in AML.

Natasha Johnson, MSN, ARNP, AOCNP
Moffitt Cancer Center
Malignant Hematology
Tampa, Florida

Natasha Johnson, MSN, ARNP, AOCNP, has no financial interests/relationships or affiliations in relation to this activity.

Natasha Johnson, MSN, ARNP, AOCNP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: including novel cytotoxic therapies such as CPX-351 and vosaroxin currently being evaluated in AML.

Nurse Reviewer
Bobbie Perrin, RN, OCN
Oncology Nurse Navigator
Harrington Cancer Center
Amarillo, Texas

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hour(s).

Providership

This CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Agios, Astellas Scientific and Medical Affairs, Inc., Celgene Corporation, and Jazz Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.